1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global PARP Inhibitors for Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Olaparib 1.2.3 Talazoparib 1.3 Market by Application 1.3.1 Global PARP Inhibitors for Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Drug Center 1.3.5 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global PARP Inhibitors for Breast Cancer Market Perspective (2016-2027) 2.2 PARP Inhibitors for Breast Cancer Growth Trends by Regions 2.2.1 PARP Inhibitors for Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 PARP Inhibitors for Breast Cancer Historic Market Share by Regions (2016-2021) 2.2.3 PARP Inhibitors for Breast Cancer Forecasted Market Size by Regions (2022-2027) 2.3 PARP Inhibitors for Breast Cancer Industry Dynamic 2.3.1 PARP Inhibitors for Breast Cancer Market Trends 2.3.2 PARP Inhibitors for Breast Cancer Market Drivers 2.3.3 PARP Inhibitors for Breast Cancer Market Challenges 2.3.4 PARP Inhibitors for Breast Cancer Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top PARP Inhibitors for Breast Cancer Players by Revenue 3.1.1 Global Top PARP Inhibitors for Breast Cancer Players by Revenue (2016-2021) 3.1.2 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Players (2016-2021) 3.2 Global PARP Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by PARP Inhibitors for Breast Cancer Revenue 3.4 Global PARP Inhibitors for Breast Cancer Market Concentration Ratio 3.4.1 Global PARP Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by PARP Inhibitors for Breast Cancer Revenue in 2020 3.5 PARP Inhibitors for Breast Cancer Key Players Head office and Area Served 3.6 Key Players PARP Inhibitors for Breast Cancer Product Solution and Service 3.7 Date of Enter into PARP Inhibitors for Breast Cancer Market 3.8 Mergers & Acquisitions, Expansion Plans 4 PARP Inhibitors for Breast Cancer Breakdown Data by Type 4.1 Global PARP Inhibitors for Breast Cancer Historic Market Size by Type (2016-2021) 4.2 Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Type (2022-2027) 5 PARP Inhibitors for Breast Cancer Breakdown Data by Application 5.1 Global PARP Inhibitors for Breast Cancer Historic Market Size by Application (2016-2021) 5.2 Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America PARP Inhibitors for Breast Cancer Market Size (2016-2027) 6.2 North America PARP Inhibitors for Breast Cancer Market Size by Type 6.2.1 North America PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) 6.2.2 North America PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) 6.2.3 North America PARP Inhibitors for Breast Cancer Market Size by Type (2016-2027) 6.3 North America PARP Inhibitors for Breast Cancer Market Size by Application 6.3.1 North America PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) 6.3.2 North America PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) 6.3.3 North America PARP Inhibitors for Breast Cancer Market Size by Application (2016-2027) 6.4 North America PARP Inhibitors for Breast Cancer Market Size by Country 6.4.1 North America PARP Inhibitors for Breast Cancer Market Size by Country (2016-2021) 6.4.2 North America PARP Inhibitors for Breast Cancer Market Size by Country (2022-2027) 6.4.3 United States 6.4.3 Canada 7 Europe 7.1 Europe PARP Inhibitors for Breast Cancer Market Size (2016-2027) 7.2 Europe PARP Inhibitors for Breast Cancer Market Size by Type 7.2.1 Europe PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) 7.2.2 Europe PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) 7.2.3 Europe PARP Inhibitors for Breast Cancer Market Size by Type (2016-2027) 7.3 Europe PARP Inhibitors for Breast Cancer Market Size by Application 7.3.1 Europe PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) 7.3.2 Europe PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) 7.3.3 Europe PARP Inhibitors for Breast Cancer Market Size by Application (2016-2027) 7.4 Europe PARP Inhibitors for Breast Cancer Market Size by Country 7.4.1 Europe PARP Inhibitors for Breast Cancer Market Size by Country (2016-2021) 7.4.2 Europe PARP Inhibitors for Breast Cancer Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size (2016-2027) 8.2 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Type 8.2.1 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) 8.2.2 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) 8.2.3 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Type (2016-2027) 8.3 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Application 8.3.1 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) 8.3.2 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) 8.3.3 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Application (2016-2027) 8.4 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region 8.4.1 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region (2016-2021) 8.4.2 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America PARP Inhibitors for Breast Cancer Market Size (2016-2027) 9.2 Latin America PARP Inhibitors for Breast Cancer Market Size by Type 9.2.1 Latin America PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) 9.2.2 Latin America PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) 9.2.3 Latin America PARP Inhibitors for Breast Cancer Market Size by Type (2016-2027) 9.3 Latin America PARP Inhibitors for Breast Cancer Market Size by Application 9.3.1 Latin America PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) 9.3.2 Latin America PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) 9.3.3 Latin America PARP Inhibitors for Breast Cancer Market Size by Application (2016-2027) 9.4 Latin America PARP Inhibitors for Breast Cancer Market Size by Country 9.4.1 Latin America PARP Inhibitors for Breast Cancer Market Size by Country (2016-2021) 9.4.2 Latin America PARP Inhibitors for Breast Cancer Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size (2016-2027) 10.2 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Type 10.2.1 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) 10.2.2 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) 10.2.3 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Type (2016-2027) 10.3 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Application 10.3.1 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) 10.3.2 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) 10.3.3 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Application (2016-2027) 10.4 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country 10.4.1 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country (2016-2021) 10.4.2 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 AstraZeneca 11.1.1 AstraZeneca Company Details 11.1.2 AstraZeneca Business Overview 11.1.3 AstraZeneca PARP Inhibitors for Breast Cancer Introduction 11.1.4 AstraZeneca Revenue in PARP Inhibitors for Breast Cancer Business (2016-2021) 11.1.5 AstraZeneca Recent Development 11.2 Everest Pharmaceuticals 11.2.1 Everest Pharmaceuticals Company Details 11.2.2 Everest Pharmaceuticals Business Overview 11.2.3 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Introduction 11.2.4 Everest Pharmaceuticals Revenue in PARP Inhibitors for Breast Cancer Business (2016-2021) 11.2.5 Everest Pharmaceuticals Recent Development 11.3 Pfizer 11.3.1 Pfizer Company Details 11.3.2 Pfizer Business Overview 11.3.3 Pfizer PARP Inhibitors for Breast Cancer Introduction 11.3.4 Pfizer Revenue in PARP Inhibitors for Breast Cancer Business (2016-2021) 11.3.5 Pfizer Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global PARP Inhibitors for Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Olaparib Table 3. Key Players of Talazoparib Table 4. Global PARP Inhibitors for Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 5. Global PARP Inhibitors for Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global PARP Inhibitors for Breast Cancer Market Size by Regions (2016-2021) & (US$ Million) Table 7. Global PARP Inhibitors for Breast Cancer Market Share by Regions (2016-2021) Table 8. Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 9. Global PARP Inhibitors for Breast Cancer Market Share by Regions (2022-2027) Table 10. PARP Inhibitors for Breast Cancer Market Trends Table 11. PARP Inhibitors for Breast Cancer Market Drivers Table 12. PARP Inhibitors for Breast Cancer Market Challenges Table 13. PARP Inhibitors for Breast Cancer Market Restraints Table 14. Global PARP Inhibitors for Breast Cancer Revenue by Players (2016-2021) & (US$ Million) Table 15. Global PARP Inhibitors for Breast Cancer Market Share by Players (2016-2021) Table 16. Global Top PARP Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PARP Inhibitors for Breast Cancer as of 2020) Table 17. Ranking of Global Top PARP Inhibitors for Breast Cancer Companies by Revenue (US$ Million) in 2020 Table 18. Global 5 Largest Players Market Share by PARP Inhibitors for Breast Cancer Revenue (CR5 and HHI) & (2016-2021) Table 19. Key Players Headquarters and Area Served Table 20. Key Players PARP Inhibitors for Breast Cancer Product Solution and Service Table 21. Date of Enter into PARP Inhibitors for Breast Cancer Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 24. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Type (2016-2021) Table 25. Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million) Table 26. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million) Table 27. Global PARP Inhibitors for Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million) Table 28. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Application (2016-2021) Table 29. Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million) Table 30. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million) Table 31. North America PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 32. North America PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 33. North America PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 34. North America PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 35. North America PARP Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 36. North America PARP Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 37. Europe PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 38. Europe PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 39. Europe PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 40. Europe PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 41. Europe PARP Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 42. Europe PARP Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 43. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 44. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 45. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 46. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 47. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region (2016-2021) & (US$ Million) Table 48. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region (2022-2027) & (US$ Million) Table 49. Latin America PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 50. Latin America PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 51. Latin America PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 52. Latin America PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 53. Latin America PARP Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 54. Latin America PARP Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 55. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 56. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 57. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 58. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 59. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 60. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 61. AstraZeneca Company Details Table 62. AstraZeneca Business Overview Table 63. AstraZeneca PARP Inhibitors for Breast Cancer Product Table 64. AstraZeneca Revenue in PARP Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 65. AstraZeneca Recent Development Table 66. Everest Pharmaceuticals Company Details Table 67. Everest Pharmaceuticals Business Overview Table 68. Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Product Table 69. Everest Pharmaceuticals Revenue in PARP Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 70. Everest Pharmaceuticals Recent Development Table 71. Pfizer Company Details Table 72. Pfizer Business Overview Table 73. Pfizer PARP Inhibitors for Breast Cancer Product Table 74. Pfizer Revenue in PARP Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 75. Pfizer Recent Development Table 76. Research Programs/Design for This Report Table 77. Key Data Information from Secondary Sources Table 78. Key Data Information from Primary Sources List of Figures Figure 1. Global PARP Inhibitors for Breast Cancer Market Share by Type: 2020 VS 2027 Figure 2. Olaparib Features Figure 3. Talazoparib Features Figure 4. Global PARP Inhibitors for Breast Cancer Market Share by Application: 2020 VS 2027 Figure 5. Hospital Case Studies Figure 6. Clinic Case Studies Figure 7. Drug Center Case Studies Figure 8. Other Case Studies Figure 9. PARP Inhibitors for Breast Cancer Report Years Considered Figure 10. Global PARP Inhibitors for Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 11. Global PARP Inhibitors for Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global PARP Inhibitors for Breast Cancer Market Share by Regions: 2020 VS 2027 Figure 13. Global PARP Inhibitors for Breast Cancer Market Share by Regions (2022-2027) Figure 14. Global PARP Inhibitors for Breast Cancer Market Share by Players in 2020 Figure 15. Global Top PARP Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PARP Inhibitors for Breast Cancer as of 2020 Figure 16. The Top 10 and 5 Players Market Share by PARP Inhibitors for Breast Cancer Revenue in 2020 Figure 17. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Type (2016-2021) Figure 18. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Type (2022-2027) Figure 19. North America PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 20. North America PARP Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 21. North America PARP Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 22. North America PARP Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 23. United States PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. Canada PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Europe PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Europe PARP Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 27. Europe PARP Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 28. Europe PARP Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 29. Germany PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. France PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. U.K. PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Italy PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Russia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Nordic PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Asia-Pacific PARP Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 37. Asia-Pacific PARP Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 38. Asia-Pacific PARP Inhibitors for Breast Cancer Market Share by Region (2016-2027) Figure 39. China PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Japan PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. South Korea PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Southeast Asia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. India PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Australia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Latin America PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Latin America PARP Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 47. Latin America PARP Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 48. Latin America PARP Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 49. Mexico PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Brazil PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Middle East & Africa PARP Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 53. Middle East & Africa PARP Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 54. Middle East & Africa PARP Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 55. Turkey PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Saudi Arabia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. UAE PARP Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. AstraZeneca Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2016-2021) Figure 59. Everest Pharmaceuticals Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2016-2021) Figure 60. Pfizer Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2016-2021) Figure 61. Bottom-up and Top-down Approaches for This Report Figure 62. Data Triangulation Figure 63. Key Executives Interviewed

AstraZeneca Everest Pharmaceuticals Pfizer